Description
AMG 820 is an investigational medication currently being studied in clinical trials for certain advanced solid tumors, including colorectal cancer. It is being tested in combination with pembrolizumab, an immunotherapy drug. The goal of the trials is to determine the safety and tolerability of AMG 820 when given with pembrolizumab and to see if AMG 820 can improve the effectiveness of pembrolizumab in treating these cancers. AMG 820 is in early-phase trials (Phase 1), meaning researchers are primarily focused on safety and determining the right dosage.
Mechanism of Action
The specific way AMG 820 works (its mechanism of action) is still being investigated in clinical trials. Researchers are studying how it interacts with cancer cells and the immune system, particularly in combination with pembrolizumab, to understand its potential anti-tumor effects.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.